18 November, 2021 - Barcelona, Spain
After successful events in London and Amsterdam in 2018 and 2019 and virtually in 2020, the 4th edition of the Hybrid AF Convergent Summit is heading to Barcelona in 2021!
Join your colleagues on 18th November for a program covering AF treatment with the Hybrid AF Convergent Therapy.
The program will explore how Hybrid AF therapies are shaping new standards of care for the most complex forms of atrial fibrillation.
Led by an international panel of speakers, the event will include sessions and roundtables on best practices, discussions on the latest clinical data, patient selection criteria and procedural considerations.
Audience
Electrophysiologists and Cardiac Surgeons who already use or would like to start a Hybrid AF Convergent Program to treat complex forms of AF.
Level
All levels
Faculty
International Faculty
Agenda
The program commences on 18th November from 09:00 until 16:00 CET
Topics include:
– Pathophysiology and current data on persistent and long-standing persistent AF
– Anatomical principles for epicardial ablation
– Program development: patient selection and intra-operative and post-operative considerations
– Understanding and troubleshooting mapping with Convergent procedure
– Review of the latest clinical evidence including CONVERGE IDE trial
– Innovation: future of epicardial ablation
– Live in box cases
Venue
Olivia Balmes Hotel – Meeting room Provenca
Carrer de Balmes 117
08008 Barcelona, Spain
Accommodation
Hotel bookings will be allocated on an individual basis and you will receive a reservation confirmation by email. Please check your travel details tab in your AF Connect dashboard for your details.
8:30 am - 8:40 am
Fundamentals of HYBRID AF Therapies
Opening remarks and introduction - R. Lee, MD (UCSF, USA)
8:40 am - 9:00 am
Past, present and future of AF management - S. Ahsan, MD (Barts Heart Center, London)
9:00 am - 9:20 am
Non-PV triggers in advanced forms of AF - R. Kaba, MD (St, Georges, London)
9:20 am - 9:35 am
LAA management options: AtriClip - T. Hanke, MD (Asklepios, Hamburg)
9:35 am - 9:50 am
LAA management options: LARIAT - K. Bartus, MD (Jagiellonian University, Krakow)
9:50 am - 11:00 am
Open Round table
F. Sebag, MD (IMM, Paris)
Why does the hybrid posterior wall isolation work?
Moderator: J. Gill MD (St. Thomas, London)
- R. Kaba, MD (St, Georges, London)
- S. Ahsan, MD (Barts Heart Center, London)
- Y. Blaauw MD (UMCG, Groningen)
11:00 am - 11:20 am
Clinical Evidence and Outcomes
Converge trial and Real World evidence - K. Makati, MD (Tampa Cardiac, USA)
11:20 am - 11:50 am
Building a Standard of Care - Y. Blaauw MD (UMCG, Groningen)
11:50 am - 12:15 pm
Hybrid AF Convergent Best Practices - E. Bergoënd, MD (Henri Mondor, Paris)
12:15 pm - 2:00 pm
Open Round table
Outcomes and funding strategies: building the clinical evidence
Moderator: R. Lee, MD (UCSF, USA)
- J. Gill, MD (St. Thomas, London)
- T. Hanke, MD (Asklepios, Hamburg)
- K. Makati, MD (Tampa Cardiac, USA)
2:00 pm - 2:20 pm
LAA Management Science Update
LAAOS III Trial lessons learnt - R. Whitlock, MD (McMaster University, Canada)
2:20 pm - 2:40 pm
aMAZE Trial first outcomes - R. Lee, MD (UCSF, USA)
2:40 pm - 4:00 pm
Procedural Considerations and Evolution of Hybrid Therapies
Case-Based round table discussion
Moderators:
- J. Yap, MD (Barts Heart Center, London)
- M. Mariani, MD (UMCG, Groningen
Convergent Challenging Cases - S. Bauer, MD (Mediclin Herzzentrum Lahr)
Orchestration and multidisciplinary conversations - A. Momin, MD (St, Georges, London)
Convergent with Thoracoscopic access - K. Zannis, MD (IMM, Paris)
Hybrid Convergent + LARIAT - C. Starck, MD (Deutsches Herzzentrum Berlin)
Hybrid Convergent + AtriClip - panelist to be announced
Standalone LARIAT - panelist to be announce